Video

Dr. Chase on Utilizing Genetic Testing to Guide Treatment Decisions in Ovarian Cancer

Author(s):

Dana Chase, MD, FACOG

In Partnership With:

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Dana Chase, MD, FACOG, a gynecologic oncologist at Arizona Oncology, and an assistant professor at the University of Arizona College of Medicine, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Over the past few years, the frontline treatment of patients with ovarian cancer has changed with the emergence of new options in the armamentarium, according to Chase. Treatment decisions can be made more rapidly, directly after biopsy or surgery, when genetic testing is performed and results are obtained, Chase says.

Utilizing certain biomarkers to guide treatment at diagnosis is a significant shift in the treatment of this population, Chase notes. The exact course of treatment for each patient can vary; however, there are options that can be impactful if they are chosen based on genetic or homologous recombination deficiency testing results, Chase concludes.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Related Content
Lora Markley, Director of Regional Managed Care for The US Oncology Network
April 19th 2024

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD
March 15th 2024

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD

Ursula A. Matulonis, MD; Robert L. Coleman, MD, FACOG, FACS; Cara Mathews, MD; Ramez N. Eskander, MD; Mansoor Raza Mirza, MD
April 10th 2023

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

Anita Kumar, MD
December 11th 2023

Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL

Jeff P. Sharman, MD
December 11th 2023

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL